Psychedelics, epilepsy, and seizures: a review
Ninon Freidel, Liliane Kreuder, Brenden Samuel Rabinovitch, Frank Yizhao Chen, Ryan S. Huang, Evan Lewis
Frontiers in Pharmacology January 12, 2024 DOI: 10.3389/fphar.2023.1326815 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Keywords | Epilepsy Population Clinical trial |
| Citations | 11 |
| Key findings | Psychedelics appear safe for use in controlled clinical settings for individuals with a history of seizures, as no evidence indicates they cause or exacerbate seizures, and some cases even show seizure remission. |
Abstract
Psychedelic compounds have been utilized by humans for centuries for medicinal, religious, and tribal purposes. Clinical trial data starting from the early 2000s and continuing today indicates that psychedelics are a clinically efficacious treatment for a variety of neurological and psychiatric disorders. However, all clinical trials examining these substances have excluded any individual with a past or current history of seizures, leaving a large cohort of epilepsy and non-epilepsy chronic seizure disorder patients without anywhere to turn for psychedelic-assisted therapy. These exclusions were made despite any significant evidence that clinically supervised psychedelic use causes or exacerbates seizures in this population. To date, no clinical trial or preclinical seizure model has demonstrated that psychedelics induce seizures. This review highlights several cases of individuals experiencing seizures or seizure remission following psychedelic use, with the overall trend being that psychedelics are safe for use in a controlled, supervised clinical setting. We also suggest future research directions for this field.
Citations in the library
Cited by 7
- Perceived changes in mental health and social engagement attributed to a single psychedelic experience in autistic adults: results from an online survey. Psychopharmacology February 1, 2025
- Psychedelics in the Treatment of Neurologic and Psychiatric Disorders: Coincidence or a New Point of View. Molecular Neurobiology June 4, 2025
- Psilocybin-Assisted Therapy for Brain Cancer Related Existential Distress: A Case-Report Journal of Palliative Medicine September 12, 2024
- Psychedelics and Autism Therapy: A Review of Current Research and Future Directions Current Issues in Molecular Biology April 18, 2026
- Severe Illness Associated with Eating Mushroom-Containing Chocolate Products — United States, January–October 2024 MMWR Morbidity and Mortality Weekly Report April 9, 2026
and 2 more in the library
Cites 33
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- NMDAR inhibition-independent antidepressant actions of ketamine metabolites Nature April 24, 2016
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs Frontiers in Human Neuroscience 2014
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
and 28 more in the library